Balanced news tone
News Sentiment
RNXT sentiment intelligence
RenovoRx Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
60 relevant articles
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-7.0% over one week, -5.9% over four weeks, trend inactive, and below fair value.
RenovoRx, Inc. Net Income (RNXT)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
76/100 classification
One-week reaction
-7.0%
Price reacting lower
Trend fit
Trend inactive
-5.9% over four weeks
Fair value
-24.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
13
Neutral
37
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
GlobeNewswire
Direct company coverage
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 12:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 12:30
- Source
- GlobeNewswire
dars.gov.et
Direct company coverage
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Loss per share misses estimates as stock declines - EBITDA Estimate Trend
- Tone
- Negative 5/100
- Event
- Earnings
- Published
- 30 May 2026 07:00
- Source
- dars.gov.et
GlobeNewswire
Direct company coverage
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 12:30
- Source
- GlobeNewswire
Investing.com Nigeria
Direct company coverage
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Investing.com Nigeria
GlobeNewswire
Direct company coverage
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 12:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 12:30
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
RenovoRx to highlight record RenovoCath revenue, pancreatic cancer trial timing
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 19 May 2026 07:00
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
RenovoRx (RNXT) Q1 2026 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 May 2026 07:00
- Source
- The Globe and Mail
Moby
Direct company coverage
RenovoRx, Inc. Q1 2026 Earnings Call Summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 12:30
- Source
- Moby
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
GuruFocus.com
Direct company coverage
RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion
- Tone
- Positive 83/100
- Event
- Earnings
- Published
- 15 May 2026 05:01
- Source
- GuruFocus.com
Investing.com
Direct company coverage
Earnings call transcript: RenovoRx Q1 2026 revenue beats forecast, stock rises
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
RenovoRx earnings missed, revenue topped estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Investing.com
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Investing.com South Africa
Direct company coverage
Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 30 Jan 2026 08:00
- Source
- Investing.com South Africa
simplywall.st
Direct company coverage
RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2026 08:00
- Source
- simplywall.st
TradingView
Direct company coverage
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jan 2026 08:00
- Source
- TradingView
simplywall.st
Direct company coverage
Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 16 Aug 2025 07:00
- Source
- simplywall.st
MarketBeat
Direct company coverage
RenovoRx (RNXT) FDA Approvals, PDUFA Dates & Drug Alerts 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2025 05:22
- Source
- MarketBeat
Zacks Investment Research
Direct company coverage
What is the current Price Target and Forecast for RenovoRx (RNXT)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 15 Aug 2022 12:24
- Source
- Zacks Investment Research
Zacks Investment Research
Direct company coverage
Should I buy RenovoRx (RNXT)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Nov 2021 18:34
- Source
- Zacks Investment Research
Stock Titan
Direct company coverage
Renovorx (RNXT) Stock News & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Sep 2021 10:04
- Source
- Stock Titan
TradingView
Direct company coverage
RNXT Stock Price and Chart — NASDAQ:RNXT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Aug 2021 04:44
- Source
- TradingView